Laura Carter, Ph.D.

Laura Carter, Ph.D. is the Chief Scientific Officer at Gossamer Bio. Dr. Carter has over 20 years of industry experience spanning target identification and validation activities through Phase 2 clinical trials in multiple disease areas and therapeutic modalities.

Prior to joining Gossamer, she was Senior Vice President, Biology at Lycera Corporation, where she led the development of several immunology and immuno-oncology clinical product candidates. Before joining Lycera, she was a Scientific Director in the Respiratory, Inflammation & Autoimmunity group at MedImmune, where she was responsible for overseeing research and development of treatments for autoimmune diseases including Uplinza® (inebilizumab-cdon).

Prior to MedImmune, Dr. Carter was a Senior Research Investigator in the Inflammation Biology and Translational Science department at Array Biopharma. She started her industry career at Wyeth, where, among other accomplishments, her basic science studies were critical in identifying and characterizing the negative regulatory role of PD-1:PD-L interactions on T-cell function.